Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Chongqing Zhifei Nixes Plan to Buy Bilthoven Biologicals

publication date: Jul 19, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Chongqing Zhifei Biological Products announced it will not pursue a plan to acquire Bilthoven Biologicals, a Dutch vaccine maker, explaining that the transaction was too risky. According to Zhifei, Bilthovern’s plans and operational methods were not what it expected. In May of this year, Zhifei announced a $93 million takeover of Bilthoven’s operations, which it positioned as a means of giving itself a foothold in Europe. More details....

Stock Symbol: (SHE: 300122)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...